Application 214275

Type
NDA
Sponsor
ACTELION

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001UPTRAVISELEXIPAGTABLET;ORAL200MCGNoNo
002UPTRAVISELEXIPAGTABLET;ORAL400MCGNoNo
003UPTRAVISELEXIPAGTABLET;ORAL600MCGNoNo
004UPTRAVISELEXIPAGTABLET;ORAL800MCGNoNo
005UPTRAVISELEXIPAGTABLET;ORAL1000MCGNoNo
006UPTRAVISELEXIPAGTABLET;ORAL1200MCGNoNo
007UPTRAVISELEXIPAGTABLET;ORAL1400MCGNoNo
008UPTRAVISELEXIPAGTABLET;ORAL1600MCGNoNo
009UPTRAVISELEXIPAGINJECTABLE;INJECTION1800MCGNoNo

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N214275-001UPTRAVISELEXIPAG1.8MG/VIALPOWDER / INTRAVENOUSRLD, RS2021-07-29

Orange Book patents#

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N214275-00172053022026-10-31U-1797Drug substance, Drug product2021-08-27
N214275-0017205302*PED2027-04-30Pediatric extension
N214275-00191738812029-08-12U-17982021-08-27
N214275-0019173881*PED2030-02-12Pediatric extension
N214275-00192842802030-06-25U-18312021-08-27
N214275-00187911222030-08-01Drug substance, Drug product2021-08-27
N214275-0019284280*PED2030-12-25Pediatric extension
N214275-0018791122*PED2031-02-01Pediatric extension

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
66215-718UPTRAVISelexipagActelion Pharmaceuticals US, Inc.NDACurrent
66215-718UPTRAVISelexipagActelion Pharmaceuticals US, Inc.NDACurrent
66215-718UPTRAVISelexipagActelion Pharmaceuticals US, Inc.NDACurrent
66215-718UPTRAVISelexipagActelion Pharmaceuticals US, Inc.NDACurrent
82595-000UPTRAVISELEXIPAGEUROFINS AMATSIGROUP SASNDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
69131ORIG2021-10-27
68260ORIG2021-08-02
68248ORIG2021-08-02